Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Beyond Skin Deep: Practical Tips on Management of DRESS/DIHS
Description
The presentation discusses the management and complications of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Drug-Induced Hypersensitivity Syndrome (DISH), highlighting the importance of an accurate diagnosis and tailored treatment strategies. A case study of a 19-year-old female who developed DRESS after starting lamotrigine illustrates the clinical evaluation process, emphasizing the significance of initiating treatment promptly upon suspicion. The presentation recommends categorizing DRESS severity (mild, moderate, severe) to guide therapy, which may include stopping the offending agent, topical steroids for mild cases, and systemic steroids for more severe reactions. The talk also addresses the potential for viral reactivation (e.g., HHV-6, EBV) in DRESS patients, highlighting the need for monitoring and possibly treating viral infections in severe scenarios. A second case describes a 39-year-old woman with severe DRESS symptoms and hospitalization; it underscores the complexities of managing acute severe cases, particularly when facing challenges like cardiac involvement and the necessity for additional immunosuppressive treatments, including cyclosporine and tofacitinib. Lastly, the discussion touches on potential long-term autoimmune sequelae post-DRESS resolution, recommending providers maintain vigilance in monitoring and addressing complications, particularly autoimmune conditions like thyroiditis. The session emphasizes ongoing patient support and education as essential in the long-term care of individuals affected by DRESS.
View moreConclusions
- The latency periods for patients suspected of DRESS may be shorter when antibiotics or iodinated contrast agents are involved.
- Management of DRESS should begin with the immediate cessation of the offending agent.
- Corticosteroids are recommended for all confirmed DRESS patients, with dosing based on severity levels.
- Mild DRESS may only require topical treatments, while moderate to severe cases typically necessitate systemic steroids.
- Relapses of DRESS are common and can occur after an initial resolution, especially with rapid tapering of steroids or exposure to new drugs.
- Viral reactivation, particularly of HHV-6, is frequent in DRESS patients and could exacerbate the condition.
- IVIG is not recommended as first-line therapy for DRESS but can be considered in cases unresponsive to steroids.
- Cyclosporine may be an alternative for patients with contraindications to corticosteroids or for those who do not respond to steroid therapy effectively.
- Long-term follow-up is essential for DRESS patients due to potential autoimmune sequelae, including autoimmune thyroid disease.
- Cho, et al. Int J or Mol Sci. 2017.
- Brüggen et al. JAMA Derm. 2024.
- Funck-Brentano et al. JAAD. 2015.
- Brin et al. Ann Dermatol Venereol. 2021.
- Emge et al. MDS. 2022.
- Singer et al. JAMA Derm. 2013.
- Sim et al. Clin Transl Sci. 2022.
- Santhamoorthy et al. Ann Indian Acad Neurol. 2012.
- Pascal et al. JAMA Derm. 2012.
- Clark et al. Dermatology Online Journal. 2020.
- Su et al. Ann Allergy Asthma Immunol. 2021.
- Picard et al. J Eur Dermatol Venereol. 2015.
- Tetart et al. JAMA Derm. 2014.
- Santiago et al. Contact Dermatitis. 2020.
- Nguyen et al. JAMA Derm. 2020.
- Kwon et al. Australas J Dermatol. 2023.
- Damsky et al. JAAD Case Rep. 2019.
- Chowdhury et al. JACC Case Rep. 2020.
- Gschwend et al. Alergo J Int. 2022.
- Radovanovic et al. J Clin Med. 2022.
- Truong et al. BMJ Case Rep. 2021.
- Daoulah et al, 2012/119.
- Kirchhof et al, 2016/217.
- Nguyen et al, 2020/518.
- Harman et al, 2003/113.
- Zuliani et al, 2005/114.
- Lee et al, 2008/115.